Инсерм (Институт Натионал Де Ла Санте Эт Де Ла Речерч Медикел)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Майметикс Корпорейшн, Инсерм (Институт Натионал Де Ла Санте Эт Де Ла Речерч Медикел)filedCriticalМайметикс Корпорейшн
Priority claimed from PCT/EP2010/051524external-prioritypatent/WO2010089402A1/en
Publication of UA106221C2publicationCriticalpatent/UA106221C2/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
The present invention deals with a method for treatment of HIV, in particular a prophylactic vaccinal method, comprising at least: administering to a patient a first antigen comprising the broadly neutralizing epitopes of the Membrane Proximal Ectodomain Region (MPER) of gp41, and administering to the same patient a second antigen comprising a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising: a N-helix region of gp41(N), a C-helix region of gp41(C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4F10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2.
UAA201109904A2009-02-062010-02-08Method for treatment of hiv
UA106221C2
(en)
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA
A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice
Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.
Immunogenic polypeptides having an immunogenic scaffold protein and a loop peptide, presenting a 3074- or 2219/2557- monoclonal antibody-targeted epitope, which is present in the hiv gp120 protein